| NCT06875128 | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease | NOT_YET_RECRUITING | PHASE2 | 2025-09 | 2029-08 | 2029-05 |
| NCT06607458 | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | RECRUITING | PHASE2 | 2025-08-05 | 2027-10 | 2026-12 |
| NCT05022901 | An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-06-10 | 2024-03-01 | 2024-03-01 |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | UNKNOWN | PHASE2, PHASE3 | 2018-04-10 | 2023-05 | 2023-01 |
| NCT02678572 | Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma | COMPLETED | PHASE3 | 2016-02-01 | 2023-08-15 | 2023-05-18 |
| NCT02406508 | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC | WITHDRAWN | PHASE2 | 2014-10 | 2017-12 | 2017-12 |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | TERMINATED | PHASE2 | 2014-06 | 2018-12 | 2018-10 |
| NCT00324727 | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma | COMPLETED | PHASE3 | 2006-02 | 2012-08 | 2012-08 |
| NCT00096083 | Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer | COMPLETED | PHASE2 | 2004-09 | 2012-08 | 2012-08 |